[开放获取]   斑秃与Th2型免疫反应

doi:10.35541/cjd.20220111

中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (11): 1013-1018.doi: 10.35541/cjd.20220111

[开放获取] 斑秃与Th2型免疫反应

章星琪

中山大学附属第一医院皮肤科，广州 510080

收稿日期:2022-02-21 修回日期:2022-07-01 发布日期:2022-11-03
通讯作者: 章星琪 E-mail:xingqi.zhang@aliyun.com

T helper type 2 immune response in alopecia areata

Xingqi Zhang

Department of Dermatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China

Received:2022-02-21 Revised:2022-07-01 Published:2022-11-03
Contact: Xingqi ZHANG E-mail:xingqi.zhang@aliyun.com

摘要/Abstract

摘要： 【摘要】斑秃的确切病因未明，部分患者反复发作。有证据显示过敏参与部分斑秃患者早发、重症、复发和迁延。尘螨过敏可能是部分重症斑秃患者尤其是儿童重症斑秃的病因之一，估计因为Th2型免疫反应占优势。脱敏可抑制Th2型免疫反应，改变机体免疫格局，降低斑秃复发时的病情严重程度。另外，斑秃治疗前高IgE水平可预测度普利尤单抗有效率较高，高白细胞介素（IL）-4水平可预示二苯环丙烯酮局部免疫疗法无效，因为该疗法通过拮抗Th1型反应而起作用。因此，血清总IgE、尘螨特异性IgE和IL-4可作为生物标志物，在斑秃患者中提示Th2型反应占优势。本文重点分析过敏与斑秃的关系、抗过敏和脱敏在治疗斑秃中的作用，旨在为斑秃的精准/个体化治疗提供思路。

关键词: 斑秃, 过敏反应, Th2细胞, 免疫球蛋白E, 白细胞介素4, JAK抑制剂, Ⅱ型炎症反应, Th2型免疫反应, 固有淋巴样细胞

Abstract: 【Abstract】 Alopecia areata （AA） is a common inflammatory and non-scarring hair loss condition with unknown pathogenesis, and relapses are common in some patients. Evidence has demonstrated that allergy takes part in the early onset, severe condition, recurrence, and prolonged process in AA. Allergy to dust mites may be one of the reasons for refractory severe AA, especially in childhood, possibly due to the predominance of T helper type 2 (Th2) immune response. Desensitization can suppress the Th2 immune response, alter the immune balance, and reduce disease severity during AA relapses. In addition, high IgE levels may predict favorable efficacy of dupilumab in AA patients before treatment, while high interleukin-4 levels may predict the ineffectiveness of topical immunotherapy with diphenylcyclopropenone, which works by antagonizing Th1 immune response. Therefore, serum total IgE, specific IgE to dust mites, and interleukin-4 can be considered as biomarkers, revealing the predominance of Th2 immune response in AA patients. This article focuses on the relationship between allergy and AA, as well as the role of anti-allergic reactions and desensitization in the treatment of AA, aiming to provide ideas for precise and individualized treatment of AA.

Key words: Alopecia areata, Anaphylaxis, Th2 cells, Immunoglobulin E, Interleukin-4, JAK inhibitors, Type Ⅱ inflammatory response, Th2-mediated immune response, Innate lymphoid cells

章星琪. [开放获取] 斑秃与Th2型免疫反应[J]. 中华皮肤科杂志, 2022,55(11):1013-1018. doi:10.35541/cjd.20220111

Xingqi Zhang. T helper type 2 immune response in alopecia areata[J]. Chinese Journal of Dermatology, 2022, 55(11): 1013-1018.doi:10.35541/cjd.20220111

参考文献 44

［1］	Zhang X, McElwee KJ. Allergy promotes alopecia areata in a subset of patients［J］. Exp Dermatol, 2020,29（3）:239⁃242. doi: 10.1111/exd.14027.
［2］	Ito T, Kageyama R, Nakazawa S, et al. Understanding the significance of cytokines and chemokines in the pathogenesis of alopecia areata［J］. Exp Dermatol, 2020,29（8）:726⁃732. doi: 10.1111/exd.14129.
［3］	Gilhar A, Laufer⁃Britva R, Keren A, et al. Frontiers in alopecia areata pathobiology research［J］. J Allergy Clin Immunol, 2019,144（6）:1478⁃1489. doi: 10.1016/j.jaci.2019.08.035.
［4］	赵莹, 张斌, 杨建, 等. 弥漫性斑秃11例临床及组织病理研究［J］. 临床皮肤科杂志, 2011,40（2）:67⁃69. doi: 10.3969/j.issn. 1000⁃4963.2011.02.002.
［5］	Zhao Y, Zhang B, Caulloo S, et al. Diffuse alopecia areata is associated with intense inflammatory infiltration and CD8+ T cells in hair loss regions and an increase in serum IgE level［J］. Indian J Dermatol Venereol Leprol, 2012,78（6）:709⁃714. doi: 10.4103/0378⁃6323.102361.
［6］	毕玉田, 吴奎, 王长征. 屋尘螨过敏原Der p1研究进展［J］. 重庆医学, 2007,36（2）:171⁃173. doi: 10.3969/j.issn.1671⁃8348. 2007.02.040.
［7］	宋洁, 张理涛. 尘螨与特应性皮炎研究进展［J］. 中国中西医结合皮肤性病学杂志, 2020,19（6）:623⁃625. doi: 10.3969/j.issn.1672⁃0709.2020.06.041.
［8］	Scalabrin DM, Bavbek S, Perzanowski MS, et al. Use of specific IgE in assessing the relevance of fungal and dust mite allergens to atopic dermatitis: a comparison with asthmatic and nonasthmatic control subjects［J］. J Allergy Clin Immunol，1999,104（6）:1273⁃1279. doi: 10.1016/s0091⁃6749（99）70024⁃2.
［9］	李水凤, 张小婷, 戚世玲, 等. 尘螨过敏可能是斑秃患者早发和重型的危险因素之一［J］. 中华皮肤科杂志, 2014,47（1）:48⁃50. doi: 10.3760/cma.j.issn.0412⁃4030.2014.01.014.
［10］	蔡泽明, 赵莹, 杨建, 等. 斑秃患者189例的疗效与临床和病理的相关关系［J］. 中国皮肤性病学杂志, 2011,25（7）:538⁃541.
［11］	Elston DM, McCollough ML, Bergfeld WF, et al. Eosinophils in fibrous tracts and near hair bulbs: a helpful diagnostic feature of alopecia areata［J］. J Am Acad Dermatol, 1997,37（1）:101⁃106. doi: 10.1016/s0190⁃9622（97）70219⁃6.
［12］	El Darouti M, Marzouk SA, Sharawi E. Eosinophils in fibrous tracts and near hair bulbs: a helpful diagnostic feature of alopecia areata［J］. J Am Acad Dermatol, 2000,42（2 Pt 1）:305⁃307. doi: 10.1016/s0190⁃9622（00）90152⁃x.
［13］	Betz RC, Pforr J, Flaquer A, et al. Loss⁃of⁃function mutations in the filaggrin gene and alopecia areata: strong risk factor for a severe course of disease in patients comorbid for atopic disease［J］. J Invest Dermatol, 2007,127（11）:2539⁃2543. doi: 10.1038/sj.jid.5700915.
［14］	西兰, 张小婷, 赵莹, 等. 斑秃患者皮损丝聚蛋白的表达［J］. 中华皮肤科杂志, 2012,45（6）:411⁃414.
［15］	Ohyama M, Shimizu A, Tanaka K, et al. Experimental evaluation of ebastine, a second⁃generation anti⁃histamine, as a supportive medication for alopecia areata［J］. J Dermatol Sci, 2010,58（2）:154⁃157. doi: 10.1016/j.jdermsci.2010.03.009.
［16］	曾子珣, 叶艳婷, 杨建, 等. 尘螨脱敏治疗在减轻斑秃复发中的作用［C］//2019全国中西医结合皮肤性病学术年会论文汇编. 江苏江阴: 中国中西医结合学会皮肤病专业委员会, 2019:123⁃124.
［17］	Guttman⁃Yassky E, Renert⁃Yuval Y, Bares J, et al. Phase 2a randomized clinical trial of dupilumab （anti⁃IL⁃4Rα） for alopecia areata patients［J］. Allergy, 2022,77（3）:897⁃906. doi: 10.1111/all.15071.
［18］	章星琪. 固有淋巴样细胞与慢性炎症性皮肤病［J］. 国际皮肤性病学杂志, 2017,43（1）:1⁃4. doi:10.3760/cma.j.issn.1673⁃4173.2017.01.001.
［19］	唐建民, 黄建林. 不同途径对尘螨脱敏的疗效观察［J］. 中国现代医生, 2008,46（13）:148⁃149. doi: 10.3969/j.issn.1673⁃9701.2008.13.094.
［20］	闫晶晶. 舌下含服粉尘螨滴剂联合氯雷他定治疗儿童过敏性哮喘伴变应性鼻炎的疗效及机制［J］. 临床与病理杂志, 2019,39（7）:1441⁃1447. doi: 10.3978/j.issn.2095⁃6959.2019.07.009.
［21］	Kageyama R, Ito T, Hanai S, et al. Immunological properties of atopic dermatitis⁃associated alopecia areata［J］. Int J Mol Sci, 2021,22（5）:2618. doi: 10.3390/ijms22052618.
［22］	Yoshimasu T, Uede M, Kanazawa N, et al. Involvement of FcɛR1α immunopositive cells in alopecia areata with atopic dermatitis and a high titer of serum immunoglobulin E［J］. Eur J Dermatol, 2014,24（4）:500⁃503. doi: 10.1684/ejd.2014.2380.
［23］	Manimaran RP, Ramassamy S, Rajappa M, et al. Therapeutic outcome of diphencyprone and its correlation with serum cytokine profile in alopecia areata［J］. J Dermatolog Treat, 2022,33（1）:324⁃328. doi: 10.1080/09546634.2020.1752887.
［24］	巩毓刚, 赵莹, 张小婷, 等. 局部免疫法治疗重型斑秃的疗效及作用机制分析［J］. 中山大学学报（医学科学版）, 2012,33（2）:216⁃222.
［25］	詹济滂, 叶艳婷, 薛紫, 等. 二苯环丙烯酮局部免疫治疗难治性斑秃的疗效分析［J］. 中山大学学报（医学科学版）, 2018,39（5）:693⁃701.
［26］	赵莹, 蔡泽明, 张斌, 等. 二苯环丙烯酮局部治疗斑秃的疗效分析［J］. 皮肤性病诊疗学杂志, 2010,17（5）:334⁃339. doi: 10.3969/j.issn.1674⁃8468.2010.05.006.
［27］	Chiricozzi A, Maurelli M, Peris K, et al. Targeting IL⁃4 for the treatment of atopic dermatitis［J］. Immunotargets Ther, 2020,9:151⁃156. doi: 10.2147/ITT.S260370.
［28］	McKenzie PL, Castelo⁃Soccio L. Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis［J］. J Am Acad Dermatol, 2021,84（6）:1691⁃1694. doi: 10.1016/j.jaad.2021.01.046.
［29］	Carnicle JM, Hendricks AJ, Shi VY. Reactivation of alopecia areata after dupilumab therapy for atopic dermatitis［J］. Dermatitis, 2021,32（1S）:e80⁃e82. doi: 10.1097/DER.00000000 00000512.
［30］	Barbarin C, Hosteing S, Nosbaum A, et al. Early onset of alopecia areata after dupilumab introduction in a patient with atopic dermatitis［J］. Eur J Dermatol, 2019,29（5）:542⁃543. doi: 10.1684/ejd.2019.3626.
［31］	Maiolini VM, Sousa NA, Marsillac PF, et al. Alopecia areata⁃like and psoriasis after dupilumab use for atopic dermatitis［J］. An Bras Dermatol, 2021,96（5）:634⁃636. doi: 10.1016/j.abd. 2021.03.005.
［32］	Jin P, Gao M, Miao X, et al. Transient alopecia areata following treatment with omalizumab in a patient with asthma and nasal polyps: a potential dermatological adverse event［J］. J Cosmet Dermatol, 2021. doi: 10.1111/jocd.14507.
［33］	Aşkın Ö, Yücesoy SN, Coşkun E, et al. Evaluation of the level of serum Interleukins （IL⁃2, IL⁃4, IL⁃15 andIL⁃17） and its relationship with disease severity in patients with alopecia areata［J］. An Bras Dermatol, 2021,96（5）:551⁃557. doi: 10.1016/j.abd.2021.03.006.
［34］	Gautam RK, Singh Y, Gupta A, et al. The profile of cytokines （IL⁃2, IFN⁃γ, IL⁃4, IL⁃10, IL⁃17A, and IL⁃23） in active alopecia areata［J］. J Cosmet Dermatol, 2020,19（1）:234⁃240. doi: 10. 1111/jocd.12970.
［35］	Marks DH, Senna MM. A potential role for IL⁃4 and IL⁃13 in an alopecia areata⁃like phenotype: a clinical perspective［J］. J Investig Dermatol Symp Proc, 2020,20（1）:S58⁃S59. doi: 10. 1016/j.jisp.2020.04.008.
［36］	Gong Y, Zhao Y, Zhang X, et al. Serum level of IL⁃4 predicts response to topical immunotherapy with diphenylcyclopropenone in alopecia areata［J］. Exp Dermatol, 2020,29（3）:231⁃238. doi: 10.1111/exd.13758.
［37］	Waśkiel⁃Burnat A, Osińska M, Salińska A, et al. The role of serum Th1, Th2, and Th17 cytokines in patients with alopecia areata: clinical implications［J］. Cells, 2021,10（12）:3397. doi: 10.3390/cells10123397.
［38］	Abercrombie M, Aleshaki J, Fivenson D. Ophiasis treated with dupilumab［J］. JAAD Case Rep, 2021,16:1⁃4. doi: 10.1016/j.jdcr.2021.07.029.
［39］	Choe S, Newman EM. Time to loss of response for dupilumab in ophiasis⁃pattern alopecia areata［J］. JAAD Case Rep, 2021,15:133⁃136. doi: 10.1016/j.jdcr.2021.07.025.
［40］	Donovan J. Successful treatment of corticosteroid⁃resistant ophiasis⁃type alopecia areata （AA） with platelet⁃rich plasma （PRP）［J］. JAAD Case Rep, 2015,1（5）:305⁃307. doi: 10.1016/j.jdcr.2015.07.004.
［41］	Lee YB, Jun M, Lee WS. Alopecia areata and poliosis: a retrospective analysis of 258 cases［J］. J Am Acad Dermatol, 2019,80（6）:1776⁃1778. doi: 10.1016/j.jaad.2018.11.033.
［42］	Jalalat SZ, Kelsoe JR, Cohen PR. Alopecia areata with white hair regrowth: case report and review of poliosis［J］. Dermatol Online J, 2014,20（9）:13030/qt1xk5b26v.
［43］	Choi H, Choi H, Han J, et al. IL⁃4 inhibits the melanogenesis of normal human melanocytes through the JAK2⁃STAT6 signaling pathway［J］. J Invest Dermatol, 2013,133（2）:528⁃536. doi: 10. 1038/jid.2012.331.
［44］	Nori M, Iwata S, Munakata Y, et al. Ebastine inhibits T cell migration, production of Th2⁃type cytokines and proinflammatory cytokines［J］. Clin Exp Allergy, 2003, 33（11）: 1544⁃1554. doi: 10.1046/j.1365⁃2222.2003.01701.x.

[1]	赵鹏秦小卫秦俊霞梁丽丽张馨中高杰. 白细胞介素18对斑秃患者自然杀伤细胞活性的调控[J]. 中华皮肤科杂志, 2022, 55(9): 778-783.
[2]	丁雨欣吕中法. 干细胞治疗斑秃的研究进展[J]. 中华皮肤科杂志, 2022, 55(9): 835-838.
[3]	黄雅馨何渊民黄书莉熊霞邓永琼. 血清几丁质酶3样蛋白1水平在寻常型天疱疮中的临床意义研究[J]. 中华皮肤科杂志, 2022, 55(6): 523-527.
[4]	中华医学会皮肤性病学分会特应性皮炎研究中心中华医学会皮肤性病学分会儿童学组. 【开放获取】度普利尤单抗治疗特应性皮炎专家共识[J]. 中华皮肤科杂志, 2022, 55(6): 465-470.
[5]	赵柳琦陈妍陈丹阳樊碧娆王瑞尚盼盼陈喜雪朱学骏王明悦. 【开放获取】度普利尤单抗治疗大疱性类天疱疮21例的疗效及安全性回顾分析[J]. 中华皮肤科杂志, 2022, 55(6): 480-485.
[6]	刘擘宋晓婷李若瑜赵作涛. 【开放获取】度普利尤单抗治疗特应性皮炎的疗效及安全性分析[J]. 中华皮肤科杂志, 2022, 55(4): 295-298.
[7]	赵鹏秦小卫秦俊霞梁丽丽张馨中高杰. 斑秃患者外周血白细胞介素35的表达及其对调节性T细胞的功能调控[J]. 中华皮肤科杂志, 2022, 55(3): 224-230.
[8]	杨晓静陈雷刚王世宁吴远慧朱由瑾安国芝周向昭孟昭影. 慢性自发性荨麻疹患者血清白细胞介素9、血小板活化因子水平与总IgE、病情严重程度和病程的相关性研究[J]. 中华皮肤科杂志, 2022, 0(2): 20220235-e20220235.
[9]	凯丽比努尔·阿卜力克木梁俊琴. 大疱性类天疱疮瘙痒相关机制的研究进展[J]. 中华皮肤科杂志, 2022, 55(10): 919-921.
[10]	蒋佳怡王大光. 非传染性炎症性甲病的诊疗进展[J]. 中华皮肤科杂志, 2022, 0(1): 20210612-e20210612.
[11]	白璐楚妍刘园园朱才勇. 慢性手部湿疹的治疗进展[J]. 中华皮肤科杂志, 2022, 0(1): 20220028-e20220028.
[12]	王钰倩乔建军方红. 国内外斑秃诊疗指南/共识比较 [J]. 中华皮肤科杂志, 2022, 0(1): 20210184-e20210184.
[13]	梁高澎宋志强. 免疫球蛋白E型自身抗体在自身免疫相关皮肤病中的研究进展[J]. 中华皮肤科杂志, 2021, 54(6): 553-556.
[14]	杨婷张考苑李子卓李旭于波窦侠. 2型固有淋巴样细胞在MC903诱导的小鼠特应性皮炎样反应中的作用[J]. 中华皮肤科杂志, 2021, 54(4): 335-341.
[15]	花玮玮龚春燕. JAK抑制剂在难治性皮肌炎中的应用进展[J]. 中华皮肤科杂志, 2021, 54(3): 264-267.

[开放获取] 斑秃与Th2型免疫反应

T helper type 2 immune response in alopecia areata

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 44

相关文章 15

Metrics

本文评价

推荐阅读 10